SCHEMBL13629810

SCHEMBL13629810

CC(=O)C1CCCN(C(C)=O)C1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.49
MAPK1 P28482 2/20 0.49
MAPT P10636 2/20 0.46
KDM4E B2RXH2 1/20 0.46
TSHR P16473 1/20 0.43
HPGD P15428 1/20 0.43
CA12 O43570 3/20 0.43
CA1 P00915 3/20 0.43
CA2 P00918 3/20 0.43
CA9 Q16790 3/20 0.43
EPHX2 P34913 2/20 0.42
LMNA P02545 2/20 0.42
EPHX1 P07099 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPK8 P45983 1/20 0.40
MAPK10 P53779 1/20 0.40
MAPK14 Q16539 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10292166 1.00 ALDH1A1 (0.49) ALDH1A1MAPK1MAPTKDM4ETSHR
SCHEMBL13804023 0.87 EPHX2 (0.44) ALDH1A1MAPK1KDM4ETSHRHPGD
SCHEMBL10086559 0.87 EPHX2 (0.44) ALDH1A1MAPK1KDM4ETSHRHPGD
SCHEMBL10086055 0.87 EPHX2 (0.44) ALDH1A1MAPK1KDM4ETSHRHPGD
SCHEMBL2460874 0.86 CA12 (0.42) ALDH1A1MAPK1MAPTTSHRHPGD
SCHEMBL1344119 0.86 ALDH1A1 (0.51) ALDH1A1MAPK1MAPTKDM4ETSHR
SCHEMBL4709618 0.86 ALDH1A1 (0.51) ALDH1A1MAPK1MAPTKDM4ETSHR
SCHEMBL6831699 0.86 ALDH1A1 (0.51) ALDH1A1MAPK1MAPTKDM4ETSHR
SCHEMBL3398264 0.84 ALDH1A1 (0.59) ALDH1A1MAPK1MAPTKDM4ELMNA
SCHEMBL3057364 0.84 ALDH1A1 (0.47) ALDH1A1MAPK1MAPTKDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3720471-B1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A COPOLYAMINO ACID ADOCIA (FR) 2023-11-29 EP disclosed
US-20220409523-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG AND A CO-POLYAMINO ACID ADOCIA (FR) 2022-12-29 US disclosed
US-20200306346-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID ADOCIA (FR) 2020-10-01 US disclosed
US-10383920-B2 Injectable solution at pH 7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals ADOCIA (FR) 2019-08-20 US disclosed
US-20170348423-A1 Injectable solution at pH 7 comprising at least one basal insulin the pl of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals ADOCIA (FR) 2017-12-07 US disclosed
US-20170348423-A1 Injectable solution at pH 7 comprising at least one basal insulin the pl of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals ADOCIA (FR) 2017-12-07 US disclosed
US-7622487-B2 Piperidine derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20090156572-A1 Nitrogen-containing heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED 2009-06-18 US disclosed
US-20090156572-A1 Nitrogen-containing heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED 2009-06-18 US disclosed
WO-2009072643-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-11 WO disclosed
US-20080275085-A1 Piperidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 US disclosed
US-20080275085-A1 Piperidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200306346-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID GCG, GLP1R, GCGR ALDH1A1 2652/4885MAPK1 1738/4885MAPT 3843/4885
US-20170348423-A1 Injectable solution at pH 7 comprising at least one basal insulin the pl of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals IAPP, IDE, INSR ALDH1A1 3464/4885MAPK1 799/4885MAPT 1805/4885
US-20080275085-A1 Piperidine derivative and use thereof TACR2, TACR1, PRLHR ALDH1A1 3412/4885MAPK1 1379/4885MAPT 4330/4885
US-20220409523-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG AND A CO-POLYAMINO ACID IAPP, INSR, GLP1R ALDH1A1 3815/4885MAPK1 1815/4885MAPT 2001/4885
US-10383920-B2 Injectable solution at pH 7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals IAPP, IDE, INSR ALDH1A1 3750/4885MAPK1 600/4885MAPT 1876/4885
US-20090156572-A1 Nitrogen-containing heterocyclic compound and use thereof NTSR2, NTSR1, HNMT ALDH1A1 2667/4885MAPK1 1405/4885MAPT 4420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.